chloroquine has been researched along with baricitinib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, Y; Han, J; Liao, C; Xie, Z; Yang, X | 1 |
| Marotto, D; Sarzi-Puttini, P | 1 |
| Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
| Askanase, AD; Buyon, JP; Khalili, L | 1 |
| Conti, F; Di Franco, M; Lucchino, B | 1 |
| Berenbaum, F; Chock, YPE; Coates, LC; Danila, MI; Duarte-García, A; Grainger, R; Jayatilleke, A; Johnson, SR; Kilian, A; Kim, AHJ; Korsten, P; Liew, J; Murad, MH; Palmerlee, C; Peirce, A; Prokop, LJ; Putman, M; Sanchez-Alvarez, C; Sattui, SE; Sparks, JA; Tam, H; Wallace, ZS | 1 |
| Wen, S; Xu, X; Yadav, AK; Yu, L | 1 |
| Giarolla, J; Parise-Filho, R; Polli, MC; Vassiliades, SV; Vaz, ES | 1 |
5 review(s) available for chloroquine and baricitinib
| Article | Year |
|---|---|
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.
Topics: Animals; Autoimmune Diseases; Drug Discovery; Humans; Models, Molecular; Protein Kinase Inhibitors; Small Molecule Libraries | 2021 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Bias; Chloroquine; COVID-19; COVID-19 Drug Treatment; Disease Progression; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Interleukin 1 Receptor Antagonist Protein; Janus Kinase Inhibitors; Proportional Hazards Models; Purines; Pyrazoles; SARS-CoV-2; Sulfonamides | 2021 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles | 2021 |
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; Dexamethasone; Drug Repositioning; Humans; Hydroxychloroquine; Ivermectin; Methylprednisolone; Pandemics; Reproducibility of Results; SARS-CoV-2 | 2023 |
3 other study(ies) available for chloroquine and baricitinib
| Article | Year |
|---|---|
What is the role of rheumatologists in the era of COVID-19?
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimalarials; Azetidines; Betacoronavirus; Chloroquine; Comorbidity; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Interleukin-1; Middle Aged; Pandemics; Physician's Role; Pneumonia, Viral; Purines; Pyrazoles; Respiratory Distress Syndrome; Rheumatic Diseases; Rheumatologists; SARS-CoV-2; Sulfonamides | 2020 |
Thoughts on COVID-19 and autoimmune diseases.
Topics: Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Humans; Hydroxychloroquine; Immunomodulation; Immunosuppression Therapy; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Rheumatology; SARS-CoV-2; Sulfonamides | 2020 |
COVID-19: an unexpected indication for anti-rheumatic therapies?
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Repositioning; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; SARS-CoV-2; Sulfonamides | 2020 |